• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    6/17/24 4:31:09 PM ET
    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email

    Gainers

    • ASLAN Pharma (NASDAQ:ASLN) shares moved upwards by 11.9% to $0.4 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million.
    • Biora Therapeutics (NASDAQ:BIOR) shares rose 11.64% to $0.75. The company's market cap stands at $26.9 million.
    • Qualigen Therapeutics (NASDAQ:QLGN) shares increased by 10.99% to $0.19. The market value of their outstanding shares is at $1.2 million.
    • CVRx (NASDAQ:CVRX) stock moved upwards by 9.48% to $12.0. The company's market cap stands at $259.1 million.
    • China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock increased by 8.68% to $0.27.
    • Fresh2 Group (NASDAQ:FRES) shares rose 7.56% to $0.34. The market value of their outstanding shares is at $8.3 million.

    Losers

    • Anitra (AMEX:AZTR) shares decreased by 21.3% to $0.18 during Monday's after-market session. The company's market cap stands at $5.3 million.
    • Mustang Bio (NASDAQ:MBIO) shares fell 15.98% to $0.63. The company's market cap stands at $17.7 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) shares declined by 14.39% to $0.12. The market value of their outstanding shares is at $2.0 million.
    • Nexalin Technology (NASDAQ:NXL) shares fell 9.2% to $0.69. The company's market cap stands at $5.0 million.
    • PAVmed (NASDAQ:PAVM) stock fell 8.92% to $0.92. The company's market cap stands at $8.6 million.
    • Tiziana Life Sciences (NASDAQ:TLSA) shares fell 8.8% to $0.72. The market value of their outstanding shares is at $73.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASLN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASLN
    $AZTR
    $BIOR
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    CVRx Inc.
    $CVRX
    5/9/2025$7.00Neutral → Underweight
    Analyst
    CVRx Inc.
    $CVRX
    1/14/2025Mkt Perform → Outperform
    William Blair
    CVRx Inc.
    $CVRX
    9/10/2024$14.00Overweight
    Cantor Fitzgerald
    CVRx Inc.
    $CVRX
    7/11/2024$18.00 → $12.00Buy
    Lake Street
    CVRx Inc.
    $CVRX
    5/1/2024$30.00 → $23.00Buy
    Craig Hallum
    CVRx Inc.
    $CVRX
    5/1/2024Outperform → Mkt Perform
    William Blair
    CVRx Inc.
    $CVRX
    5/1/2024$36.00 → $13.00Overweight → Neutral
    JP Morgan
    CVRx Inc.
    $CVRX
    1/31/2023$20.00Buy
    Lake Street
    More analyst ratings

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sparks Ronald M was granted 150,000 shares, increasing direct ownership by 231% to 215,000 units (SEC Form 4)

    4 - PAVmed Inc. (0001624326) (Issuer)

    10/2/25 4:22:08 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    Director White Debra was granted 150,000 shares, increasing direct ownership by 231% to 215,000 units (SEC Form 4)

    4 - PAVmed Inc. (0001624326) (Issuer)

    10/2/25 4:21:10 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    Director Baxter Timothy E was granted 150,000 shares, increasing direct ownership by 231% to 215,000 units (SEC Form 4)

    4 - PAVmed Inc. (0001624326) (Issuer)

    10/2/25 4:20:04 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    SEC Filings

    View All

    Qualigen Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

    10/3/25 5:27:31 PM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    10/3/25 4:59:09 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Tiziana Life Sciences Ltd.

    6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

    10/3/25 4:30:01 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azitra Receives Notice of Non-Compliance from NYSE American

    BRANFORD, Conn., Oct. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. Section 1003(a)(ii) requires a listed company to have stockholders' equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Azitra is subject to the procedures and requiremen

    10/3/25 4:45:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)

    New York, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of $41 million strategic investment in its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen Therapertics"), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, from its client Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company. The total investment amounts to approximately $41 million

    9/30/25 4:00:00 PM ET
    $FFAI
    $QLGN
    Auto Manufacturing
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

    BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has been invited to attend the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2025 in Collaboration with KAIMRC, taking place October 1–2, 2025, at the King Saud bin Abdulaziz University for Health Sciences Conference Center in Riyadh, Saudi Arabia. The 2025 Life Science Innovation Forum (LSIF) is a two-day international event hosted in Riyadh, Saudi Arabia

    9/30/25 8:30:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nielsen Kirk G. bought $59,795 worth of shares (10,966 units at $5.45) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/19/25 6:46:37 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Nielsen Kirk G. bought $977,346 worth of shares (187,813 units at $5.20) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/14/25 5:27:07 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $7,775 worth of shares (1,650 units at $4.71), increasing direct ownership by 49% to 5,050 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/13/25 7:12:40 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVRx, Inc. downgraded by Analyst with a new price target

    Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

    5/9/25 8:41:10 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx, Inc. upgraded by William Blair

    William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform

    1/14/25 7:51:14 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on CVRx, Inc. with a new price target

    Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00

    9/10/24 7:46:21 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

    HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, as Chief Financial Officer, effective August 1, 2025. Mr. Van Fleet brings more than 20 years of experience in public accounting and assurance services, most recently serving as Partner at Marcum LLP (formerly Friedman LLP). In this role, he led the firm's assurance practice and advised both publicly traded and privately held clients across a wide range of sectors including technology, life sciences, manufacturing, and distribution. He

    8/1/25 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Financials

    Live finance-specific insights

    View All

    Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

    Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advisory Committee ("CAC") Meeting convened by MolDX-participating Medicare Administrative Contractors as part of the reconsideration of Local Coverage Determination (LCD) L39256, "MolDX: Molec

    9/5/25 9:16:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    CVRx Reports Second Quarter 2025 Financial and Operating Results

    MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025. Recent Highlights Total revenue for the second quarter 2025 was $13.6 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2025 was $12.1 million, an increase of 15% over the prior year quarterActive implanting centers in the U.S. grew to 240, an increase of 27% since June 30, 2024CMS propo

    8/4/25 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 31, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, August 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's secon

    7/31/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mustang Bio Inc.

    SC 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)

    11/14/24 4:21:44 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:56:51 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:18:21 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care